Nasal vaccine could shield newborns from whooping cough
NCT ID NCT01188512
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tested a new whooping cough vaccine given as a nasal spray. 48 healthy adult men received either the vaccine or a placebo to check safety and immune response. The goal is to develop a single-dose vaccine that can protect infants from birth, before they get their regular shots.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PERTUSSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Karolinska University Hospital
Solna, 171 76, Sweden
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new vaccine shield older kids and adults from three deadly infections?
- Can a Five-Part vaccine bolster protection against three serious infections?
- Will a single DTP vaccine dose protect for a decade? study tracks antibodies
- Scientists create controlled whooping cough infection to speed up vaccine research
- New vaccine for moms could shield babies from whooping cough
- Nasal whooping cough vaccine gets a boost: higher dose tested in adults